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Abstract
Background: BRCA1 and BRCA2 account for the majority of the known familial breast cancer risk,
however, the impact of other cancer susceptibility genes largely remains to be elucidated.
Checkpoint Kinase 2 (CHEK2) is an important signal transducer of cellular responses to DNA
damage, whose defects have been associated with an increase in breast cancer risk. Previous studies
have identified low penetrance CHEK2 alleles such as 1100delC and I157T, as well as variants such
as S428F in the Ashkenazi Jewish population and IVS2 + 1G>A in the Polish population. No founder
allele has been specifically identified in the French Canadian population.
Methods: The 14 coding exons of CHEK2 were fully sequenced for variant alleles in a panel of 25
affected French Canadian women and 25 healthy controls. Two variants were identified of which
one novel variant was further screened for in an additional panel of 667 breast cancer patients and
6548 healthy controls. Additional genotyping was conducted using allele specific PCR and a
restriction digest assay. Significance of amino acid substitutions were deduced by employing
comparative analysis techniques.
Results: Two variants were identified: the previously reported silent substitution 252A>G (E84E)
and the novel missense variant, 1217G>A (R406H). No significant difference in allele distribution
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between French Canadian women with breast cancer and healthy controls was observed (3/692,
0.43% vs. 22/6573, 0.33%, respectively, P = 0.73).
Conclusion: The novel CHEK2 missense variant identified in this study, R406H, is unlikely to
contribute to breast cancer risk in French Canadian women.
Background
Breast cancer is the most common form of malignancy
amongst females in the western world. Specifically, one in
ten of all new diagnosed cancer cases are of the female
breast [1]. Typically, less than five percent of these cases
are inherited in a mendelian fashion, specifically from the
segregation of highly penetrant alleles, such as mutations
in BRCA1 and BRCA2 [2]. The existence of a large number
of breast cancer families who lack linkage to either BRCA1
or BRCA2 [3] suggested that other breast cancer suscepti-
bility genes remained undiscovered. One such candidate
gene, CHEK2, encodes a multifunctional kinase enzyme
involved in the induction of cell cycle arrest, DNA repair
and apoptosis [4-6]. Several large-scale studies have char-
acterized known variants of the CHEK2 gene [7-9], con-
clusively proving that CHEK2 is a breast cancer
susceptibility gene.
One CHEK2 mutation present in the general population,
1100delC, occurs independently of BRCA1/2 mutations
[7,8]. The 1100delC variant results in a premature stop
codon within exon 10, impairing the kinase ability of the
enzyme and resulting in a two-fold increase in breast can-
cer risk [7,8,10]. In general, the population frequency of
1100delC has been reported to be ~1.9% in individuals
with breast cancer, compared to ~0.7% in those without
[10]. There is, however, variation in the observed fre-
quency of 1100delC [10-13] suggesting that the preva-
lence of this mutation varies amongst populations.
Population isolates, also known as founder populations,
have reduced genetic heterogeneity and are valuable tools
for genetic analysis involving cancer susceptibility. A
recent example of such an approach has been seen with
the identification of the CHEK2 S428F mutation in the
Ashkenazi Jewish population, which has been associated
with a relative breast cancer risk of 2.0 amongst Ashkenazi
Jewish women [14]. Similarly, a splice site mutation, IVS2
+ 1G>A, originally identified in a US patient with familial
prostate cancer [15], has been identified as a founder
mutation in the Polish population with a population fre-
quency of 0.3% [16]. The allele is associated with a two-
to four-fold elevated risk for prostate, as well as a moder-
ate increase in risk for breast cancer [16,17]. Most recently,
Walsh et al. [18] discovered a novel 5.4 Kb deletion, lead-
ing to a loss of exons 9 and 10, in two families of Central
European ancestry. This mutation was found in 1.3% of
631 patients and in none of the 367 healthy controls. Fur-
ther analysis of CHEK2  may reveal additional founder
mutations in other populations. One such population yet
to be investigated, and the focus of this study, is the
French Canadian population.
Established in Quebec between 1608 and 1760, the pop-
ulation now includes approximately 6 million French
Canadians, who are descendants of an estimated 8000–
10000 migrants from France [19]. Altogether, approxi-
mately 80% of these founders still have descendants in
Quebec today, and they account for the major part of the
French Canadian gene pool [20]. Many of the hereditary
disorders in the French Canadian population show evi-
dence of founder effects (for review, see [19]). In particu-
lar, French Canadian founder mutations have been
identified in BRCA1, BRCA2 and PALB2 [21-24].
In the current study, we examined a panel of 25 BRCA1/2
negative, affected French Canadian women alongside 25
healthy controls, to investigate the impact of CHEK2 vari-
ants on breast cancer susceptibility in the French Cana-
dian population.
Methods
Study Population
French Canadian women, previously affected by breast
cancer, and determined through sequencing to be nega-
tive for all exonic BRCA1  and BRCA2  mutations, were
used for SNP discovery (n = 25). Cases had a family his-
tory of breast cancer with at least three cases of either
breast cancer diagnosed before 65 years of age, male
breast cancer, or ovarian cancer within three degrees from
the index case [21]. Healthy French Canadian women
with unknown BRCA1/2  mutation status were used as
controls (n = 25). Controls were requited either through
random dialing or as spouses of cases ascertained for pre-
vious studies of cancer, in the French Canadian popula-
tion (Group 1, n = 50).
Variants identified in the initial case/control group were
further screened for in extended groups of breast cancer
cases and unaffected controls, using the original carrier
samples as a positive control. Group 2 consists of cases (n
= 124) which were tested, and found negative, for French
Canadian  BRCA1/2  mutations reported by Tonin et al
[21]. Women included in this group were diagnosed at a
mean age of 54 (range = 26–76) years old and were
referred to cancer genetics clinics at McGill University hos-BMC Cancer 2008, 8:239 http://www.biomedcentral.com/1471-2407/8/239
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pitals. Patients included in Group 2 were selected for
either a high risk family history of at least three cases of
breast and/or ovarian cancer within three degrees from
the index case, or for presentation of multiple consecutive
breast cancer cases prior to the age of 76. Cases included
in this panel were genotyped alongside a subset of healthy
French Canadian women, recruited through random dial-
ing, in the clinic or as spouses of cases from previous
investigations, as controls (n = 116). Group 3 includes an
extended group of French Canadian women (n = 543)
previously diagnosed with breast cancer at Hotel-Dieu
Hospital, Montreal, at a mean age of 47 (range = 26–65)
years old. All women in this group had previously been
tested and found negative for French Canadian BRCA1/2
founder mutations. Recruited patients were either under
50 years of age at diagnosis, or were diagnosed between
50 and 65 and had a first degree relative with breast can-
cer. Group 4 consists of a panel of French Canadian neo-
natal controls (n = 6432), which have been previously
tested for several known PALB2 variants [24] as well as the
known  BRCA1  and  BRCA2  French Canadian founder
mutations.
All patients have provided written consent to participate
in current research based investigations. The study is in
compliance with the Helsinki declaration, and has been
granted ethical approval by the institutional review
boards of McGill University and the University of
Toronto.
Molecular methods
Genotyping
SNP discovery was performed on Group 1 by direct PCR
and sequencing (sequencing was conducted by the McGill
University and Genome Quebec Innovation Center in both the
forward and reverse directions). Sequencing was per-
formed on all of the 14 coding exons of CHEK2 as well as
at the intron/exon boundaries. Primers used for PCR were
designed using the online Primer3 program (Primer3). All
primers used, annealing temperatures and amplicon sizes
are summarized in Table 1.
Long Range PCR
Any variants found within exons 10–14, which are known
to be duplicated wholly or in part on various chromo-
somes, were reamplified via long range PCR; a ~9.2 Kb
fragment encompassing exons 10–14 was generated using
primers F5'-CGACGGCCAGTCTCAAGAAGAGGACT-
GTCTT-3' and R5'-GCTATGACCATGCACAAAGCCCAG-
GTTCCATC-3' as previously described [14]. PCR was
conducted using the Expand Long Template PCR system
(Roche Applied Science, Cat No. 1-681-834) with an
annealing temperature of 58°C.
Products obtained from Long-range PCR were then used
as a template in a second round of amplification, using
appropriate primers to isolate individual exons for
sequencing.
Allele-Specific PCR
To determine the frequency of 1217G>A in Group 2, a for-
ward primer with the last nucleotide specific to the variant
was designed and used in conjunction with the exon 10
primers designed for sequencing. PCR was conducted at
an annealing temperature of 54°C and the product was
visualized by gel electrophoresis.
Allele-specific amplification was preformed as above for
Group 4 which was followed by fluorometric detection of
the PCR product using SybrGreen. A scatter plot was
derived from the raw fluorescence of both alleles which
was then analyzed to compute the genotype as previously
described [25]. The accuracy of this method is 99.0% and
the average rate of data rejection is below 1.00%.
Restriction Assay
Samples from Group 3 were genotyped via a restriction
digest assay. Samples were amplified by PCR twice: the
first to isolate CHEK2  exon 10, and the second using
nested primers to obtain a smaller fragment of 202 bp,
encompassing 1217G>A. Products obtained from the sec-
ond round of amplification were incubated overnight at
37°C with +NlaIII (1 U/sample, New England BioLabs,
USA). NlaIII digests after the consensus sequence of
CATG, and thus cut the variant (A) allele, resulting in
three fragments of 4, 76 and 122 bp, respectively. After
digest, the wildtype CHEK2 allele results in two fragments
of 4 and 198 bp, respectively. A sample mutant for R406H
(confirmed by sequencing) and a wild-type sample were
randomly seeded on each 96-well plate and used as posi-
tive and negative controls respectively in the screening
process. Digested products were visualized by gel electro-
phoresis. The presence of 1217G>A was confirmed by
direct sequencing using the BigDye®  Terminator v1.1
Cycle Sequencing Kit and 3130 × l Genetic Analyzer
(Applied Biosystems, USA).
1100delC mutation Analysis
The presence of 1100delC within samples encompassing
Group 2 was determined by generating S-35 labeled PCR
products. PCR product was denatured for 15 min at 95°C
prior to loading in a 5% denaturing polyacrylamide gel.
PCR products were separated for 2 hours at 80W and vis-
ualized by audioradiography.
Amino Acid stability, conservation and severity
To estimate the impact of amino acid substitutions on
phenotype, mean chemical distance between the wild
type amino acid and its substitute was evaluated using theBMC Cancer 2008, 8:239 http://www.biomedcentral.com/1471-2407/8/239
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Grantham matrix score (Grantham, 1974), Grantham var-
iation (GV) and Grantham deviation (GD). Conservation
of the wild type amino acid was analyzed using the multi-
ple sequence alignment program ClustalW. Substitution
tolerance was estimated using the SIFT algorithm (Sorting
Intolerant From Tolerant).
Statistical analysis
Allele and genotype frequency is expressed as a propor-
tion of the entire sample set. Fisher's exact test was used to
test for significance. In the circumstance where a sample
would not amplify, it was excluded from all calculations.
Two-tailed p values are presented.
Results
SNP discovery in CHEK2 coding regions was conducted
by sequencing 25 cases and 25 controls simultaneously.
This approach provides an 80% power to detect an allele
with a frequency of 1% or more [26]. Furthermore, this
eliminates the potential biases inherent when studying
cases first and then searching for only those variants iden-
tified, in the control set. From this, we have identified two
variants: the previously reported silent variant, 252A>G
(E84E), observed in 2/25 cases versus 2/25 controls, in
addition to the novel missense variant 1217G>A, which
results in an amino acid substitution at position 406, of
an arginine for a histidine (R406H, Figure 1) observed in
1/25 cases.
The missense mutation, R406H was further screened for
in extended groups of cases and controls. Through allele-
specific PCR, we identified one additional affected case
(1/124, 0.81%) from Group 2. Group 3 was genotyped by
a restriction assay and was found to contain one affected
case (1/543, 0.18%). Within our neonatal set of controls,
Group 4, R406H was observed in 22 samples (22/6432,
0.34%). Overall, the frequency of the R406H allele was
not significantly elevated in total breast cancer cases (3/
Table 1: CHEK2 Primers and Details
Fragment Size (bp) Exon Amino Acid Primers (5'->3') Annealing 
Temp.(°C)
CHEK2EX01 565 1 1–106 Forward: gaactataggtctgggctgttagg
Reverse: tccacctggtaatacaactttctg
57
CHEK2EX02 582 2&3 107–197 Forward: tgccttcttaggctattttcctac
Reverse: aaccatattctgtaaggacaggac
56
CHEK2EX04 354 4 198–228 Forward: ctcaagggctttacaatatg
Reverse: gaaatgagaaaccaccaatc
54
CHEK2EX05 499 5 229–264 Forward: gaatttcacaatccagggctac
Reverse: ctcacaaattcatccatctaagcag
56
CHEK2EX06 632 6 265–282 Forward: tagagctgggtttggaactcag
Reverse: agctaggcatgtgtgtgaatg
68
CHEK2EX07 434 7 283–304 Forward: aagaagactgggaagagacctagc
Reverse: gcaagcctacattagattctttgg
56
CHEK2EX08 365 8 305–336 Forward: catctcattccttagtttccaactg
Reverse: tctgcctaattcagggagtaattc
56
CHEK2EX09 331 9 337–365 Forward: ctgtgagatgtgtgtgttggtaac
Reverse: tctggataagagcagtatcacctg
58
CHEK2EX10 546 10 366–420 Forward: ttaatttaagcaaaattaaatgtcc
Reverse: ggcatggtggtgtgcatc
54
CHEK2EX11 353 11 421–458 Forward: gctgggattacaagcctaagg
Reverse: gaagaaactcccaccacagc
69
CHEK2EX12 541 12 459–487 Forward: ggcctgttaattctggcatactc
Reverse: aaaggttgtagcctggccag
67
CHEK2EX13 488 13 488–514 Forward: cctctgggaaggtagaggc
Reverse: caatccctagctgtgcttatcg
66
CHEK2EX14 585 14 515–543 Forward: cccccactttactggaagc
Reverse: gcaaaaccctgtctctacaaaat
64
CHEK2 R406H Allele Specific N/A 10 N/A Forward: ggactgctgggtataacca 54
CHEK2 Long Range ~9,200 10–14 366–543 Forward: cgacggccagtctcaagaagaggactgtctt
Reverse: gctatgaccatgcacaaagcccaggttccatc
58
CHEK2 Restriction 546 10 366–420 Forward : ttaatttaagcaaaattaaatgtc Reverse : ggcatggtggtgtgcatc 57
CHEK2 Restriction Nested 202 10 380–420 Forward: catgagaaccttatgtggaaccc
Reverse: cctggacaacagagcaagacacat
58
CHEK2 1100delC Sizing 196 10 366–396 Forward:aatagaaactgatctagcctacgtgt
Reverse: gaacttcaggcgccaagt
60
Summary of primers, annealing termperatures and PCR amplicon sizes for the 14 coding exons of CHEK2. Additional details are listed for primers 
used for Long Range PCR, R406H and 1100delC genotyping.BMC Cancer 2008, 8:239 http://www.biomedcentral.com/1471-2407/8/239
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692, 0.43%) compared with healthy controls (22/6573,
0.33%) P = 0.73 (Table 2).
To predict the significance of the R406H substitution,
sequence alignment of CHEK2  exon 10 was analyzed
across ten species, revealing a modest conservation of the
arginine residue amongst higher eukaryotes, with 6/10
species displaying homology (Table 3). When comparing
the mean chemical difference between arginine and histi-
dine, a Grantham score of 29, GV of 124.29 and a GD of
0.0 is obtained, suggesting the neutrality of this substitu-
tion. Furthermore, tolerance of this substitution is indi-
cated via analysis by the SIFT algorithm (SIFT score of
0.10).
Additionally, patients included in Group 2 were further
genotyped for 1100delC. Including the fully sequenced 25
cases and controls, 1100delC was observed in 2.01% (3/
149) of cases versus 0.7% (1/141) of controls.
Discussion
Inherited breast cancer has been associated with germline
mutations in more than ten different genes, most of which
are involved in the maintenance of genomic integrity. A
large proportion of such cases can be accounted for by
mutations in the tumor suppressor genes BRCA1  and
BRCA2. Additionally, TP53, PTEN, CDH1 and STK11 are
considered high-risk breast cancer susceptibility genes.
Mutations in ATM, BRIP1, PALB2, CHEK2 and possibly
E84E and R406H Figure 1
E84E and R406H. A) Chromatogram of the silent E84E with arrow illustrating its location N' Terminal to the CHEK2 fork-
head association domain. B) Chromatogram of R406H and its location within the CHEK2 Kinase domain.
Table 2: CHEK2 1217G>A Frequency
Group BRCA CTRL P-Value
1 4.00% (1/25)* 0.00% (0/25)* 1.00
2 0.81% (1/124)* 0.00% (0/116)* 1.00
3 0.18% (1/543) N/A N/A
4 N/A 0.34% (22/6432) N/A
Total 0.43% (3/692) 0.33% (22/6573) 0.73
*Genotyped for 1100delC which was observed in 2.01% (3/149) of 
cases vs 0.7% (1/141) controls. If we compare the frequency in cases 
with that seen in the same neonatal controls used in this study, that 
were also tested for 1100delC by Zhang et al [30] (19 1100delC 
carriers among 6460 controls), then the difference between cases and 
controls is statistically significant (P = 0.01).BMC Cancer 2008, 8:239 http://www.biomedcentral.com/1471-2407/8/239
Page 6 of 8
(page number not for citation purposes)
NBS1, RAD50 are also associated with a moderately
increased risk for breast cancer, and many low penetrance
genes have recently been identified. However, roughly
50% of familial breast cancers remain to be elucidated
[27,28].
In the current study, 25 French Canadian breast cancer
patients and 25 healthy controls were fully screened for
variants within the CHEK2 gene. Two variants were iden-
tified: the silent variant E84E and the novel R406H mis-
sense variant. E84E, which has been reported in several
other CHEK2 screens, is likely a neutral allele with no
association to breast cancer [14,29,30]. In addition, given
that the primary structure of CHEK2 is unaltered by the
E84E mutation, and further, that it was observed at a sim-
ilar frequency in cases and controls suggests against the
possibility that this variant may affect an exonic splicing
enhancer or aberrantly affect protein translation rates.
Thus, no further investigation of this variant was con-
ducted. R406H, however, was genotyped for in an
extended panel of breast cancer cases and healthy con-
trols. Neither variant was observed at a significantly high
frequency in breast cancer cases when compared with con-
trols.
To further characterize any potential impact of R406H,
bioinformatic tools were employed. In short, conserva-
tion analysis, substitution evaluation and a tolerance test
lack any indication of a pathogenic contribution from this
allele.
Large international studies [10,31-33] have shown that
1100delC is associated with increased breast cancer risk in
many, but by no means all, world populations. Our find-
ings in cases (Table 2) when combined with previous data
on controls [32] suggest that this allele is also associated
with breast cancer risk in the French Canadian popula-
tion. The evidence that other CHEK2 alleles are associated
with an increased risk in the general population is less
convincing [34,35]. However, some founder alleles that
do seem to be associated with an increased risk in specific
populations have been identified.
To date, five interesting CHEK2 founder alleles have been
identified, all of which are associated with an elevated risk
for breast: 1100delC, I157T, IVS2 + 1G>A, S428F and
del5395. All five variants have been shown to contribute
to breast cancer risk provided they are present in the pop-
ulation of interest, with the latter three particularly being
observed with high degree of ethnic specificity. The IVS2
+ 1G>A splicing mutation has been observed in the Polish
population as a founder mutation with a 0.3% popula-
tion frequency [36] and associates with approximately a
two-fold elevated risk for breast cancer. In the Ashkenazi
Jewish population, Shaag et al [14] discovered the novel
missense mutation S428F (1283C>T) at a frequency of
2.88% amongst 1632 breast cancer patients compared to
1.37% of 1673 controls, thus suggesting S428F is associ-
ated with breast cancer risk; a yeast complementation
assay supported the hypothesis that this variant aberrantly
affects CHEK2 protein function. The most recently identi-
fied founder mutation, del5395, resulting in a loss of
exons 9 and 10, was originally identified in two families
of Czech or Slovak origin [18]. This founder mutation has
twice been studied in detail; the first observing the dele-
tion in 1.3% of 631 breast cancer cases and 0.0% of 367
healthy controls from the Czech and Slovak Republics. In
agreement with the first study, Cybulski et al [37] investi-
gated the 5,395 bp deletion in Poland, observing the fre-
quency to be 0.9% of 4,454 breast cancer cases versus
0.4% of 5,496 healthy controls (OR = 2.0; 95% CI = 1.2–
3.4). It is likely other CHEK2 founder mutations are yet to
be discovered, as to date, CHEK2 has not been thoroughly
investigated in many ethnic groups.
One such group, the French Canadian population has
proved to be valuable in investigations of other breast
cancer susceptibility genes. For example, several common
pathogenic BRCA1/2 founder mutations are recognized in
the French Canadian population [21-23]. Moreover, the
proposition that additional French Canadian founder
mutations have yet to be revealed is supported by the
recent identification of a PALB2  truncating mutation,
Q775X [24].
Table 3: Sequence Alignment of CHEK2 Exon 10
Mosquito VSDFGSSKFLDHTIFMRTICGTPEYVAPEVLESNGQKPYTRQVDVWSLGVVLYTM --256
Fruit Fly VSDFGLSKFVQKDSVMRTLCGTPLYVAPEVLITGGREAYTKKVDIWSLGVVLFTC --376
Homo Sapiens ITDFGHSKILGETSLMRTLCGTPTYLAPEVLVSVGTAGYNRAVDCWSLGVILFIC --420
Chimpanzee
Dog ITDFGQSKILGETSLMRTLCGTPTYLAPEVLNSFGTAGYNRAVDCWSLGVILFIC --421
Mouse ITDFGQSKILGETSLMRTLCGTPTYLAPEVLVSNGTAGYSRAVDCWSLGVILFIC --424
Rat ITDFGQSKILGETSLMRTLCGTPTYLAPEVLISNGTAGYSRAVDCWSLGVILFIC --423
Chicken -TYFGQSKILGETSLMKTLCGTPTYLAPEVLNSFGTAGYSRAVDCWSLGVILFVC --391
Fugu VTDFNQSRILEETMLMRTLCGTPSYLAPEVFTQASTTGYSLAVDAWSLGVLLFVC --396
Tetraodon VTDFNQSRILEETMLMRTLCGTPSYLAPEVFTQASTSGYGLAVDAWSLGVLLFVC --430
C. Elegans LTDFGMAKNSVN--RMKTHCGTPSYCAPEIVANQG-VEYTPKVDIWSLGCVLFIT --370BMC Cancer 2008, 8:239 http://www.biomedcentral.com/1471-2407/8/239
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The results presented here represent the first systematic
analysis of CHEK2 in the French Canadian population.
The novel variant we identified, R406H, is almost cer-
tainly not associated with increased risk for breast cancer
and CHEK2 alleles other than 1100delC are unlikely to
contribute to breast cancer risk in this population. How-
ever, the possibility that CHEK2, due to its role in cell
cycle regulation, may influence the risk of other familial
cancers in the French Canadian population, such as pros-
tate, colon, ovarian or colorectal cancer, and would thus
be an informative population for such future investiga-
tions. Interestingly, some of the well known variants, such
as I157T have been associated with colon cancer [38],
whereas the truncating variants 1100delC and IVS2 +
1G>A have been associated with an elevated risk for famil-
ial prostate cancer in both the Polish and Finish popula-
tion [16]. Most recently, all three variants in addition to
the del5395 have been associated with an increased sus-
ceptibility to bladder cancer in Poland [39].
The emerging picture suggests that some functionally sig-
nificant variants in CHEK2 are able to predispose cells
from a wide distribution of organs to an elevated risk of
cancer. Thus, much remains to be studied with respect to
CHEK2  alleles in the French Canadians, but it seems
unlikely that a specific, common founder mutation for
breast cancer exists in this population.
Conclusion
Sequencing of the CHEK2  gene in 25 breast cancer
patients and 25 healthy controls, from the French Cana-
dian population did not reveal any pathogenic mutations.
The one novel missense variant identified in this study,
R406H, does not appear to be associated with breast can-
cer risk. Additional investigations of CHEK2 and French
Canadian breast cancer, utilizing large panels of familial
and/or sporadic cases, would be necessary to refute the
notion that additional CHEK2 susceptibility alleles exist
in the French Canadian population. However, it is
unlikely that CHEK2 alleles other than 1100delC signifi-
cantly influence familial breast cancer risk within our
study group.
Note added in Proof: We have recently completed MLPA
(MRC-Holland, kit P190) analysis on 41 French Canadian
women with a personal and familial history breast cancer.
Cases had previously been screened for all known founder
BRCA1  and  BRCA2  mutations, as well as CHEK2
1100delC. No genomic deletions or insertions were iden-
tified.
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